Expression and clinical significance of MAGE and NY‐ESO‐1 cancer‐testis antigens in adenoid cystic carcinoma of the head and neck. Issue 7 (13th February 2016)

• Record Type: Journal Article
• Authors: Veit, Johannes A.; Heine, Daniela; Thierauf, Julia; Lennerz, Jochen; Shetty, Subasch; Schuler, Patrick J.; Whiteside, Theresa; Beutner, Dirk; Meyer, Moritz; Grünewald, Inga; Ritter, Gerd; Gnjatic, Sacha; Sikora, Andrew G.; Hoffmann, Thomas K.; Laban, Simon
• Is Part Of: Head & neck. Volume 38:Issue 7(2016)
• Page Start: 1008
• Page End: 1016
• Publication Date: 2016-02-13
• Subjects: adenoid cystic carcinoma -- head and neck cancer -- cancer‐testis antigens -- Melanoma antigen -- New York esophageal squamous cell carcinoma (NY‐ESO‐1); Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.24403
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer‐testis antigens (CTAs) represent an immunogenic family of cancer‐specific proteins and thus represent an attractive target for immunotherapy. Methods: Eighty‐four cases of ACC were identified, the CTAs pan‐Melanoma antigen (pan‐MAGE; M3H67) and New York esophageal squamous cell carcinoma (NY‐ESO‐1; E978) were detected immunohistochemically (IHC) and correlated with clinical data. Results: Expression of NY‐ESO‐1 was found in 48 of 84 patients (57.1%) and of pan‐MAGE in 28 of 84 patients (31.2%). Median overall survival (OS) in NY‐ESO‐1 positive versus negative patients was 130.8 and 282.0 months ( p = .223), respectively. OS in pan‐MAGE positive versus negative patients was 105.3 and 190.5 months, respectively ( p = .096). Patients expressing both NY‐ESO‐1 and pan‐MAGE simultaneously had significantly reduced OS with a median of 90.5 months compared with 282.0 months in negative patients ( p = .047). Conclusion: A significant fraction of patients with ACC show expression of the CTAs NY‐ESO‐1 and/or pan‐MAGE with promising immunotherapeutic implications. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1008–1016, 2016